TG Therapeutics Inc. (TGTX)
NASDAQ: TGTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Pre-market: 52.80 -0.28%
TGTX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $8.11B
- P/E (TTM)
- 19.25
- Forward P/E
- 19.55
- EPS (TTM)
- $2.75
- Dividend yield
- None
- 52-week range
- 26.76 – 59.30
- Day range
- 51.41 – 53.88
- Volume / Avg
- 1.51M / 2.01M
- Beta
- —
- Shares outstanding
- 153.08M
- Next earnings
- Nov 2, 2026
52-week range
TGTX stock today
On Oct 7, TGTX ended the session at $52.95, adding $0.76 (1.46%), versus the S&P 500's 0.22% decline. Shares are 10.7% below their 52-week high of $59.30, set on Jul 9, 2026 and 97.9% above the 52-week low of $26.76, near the top of the past year's range. TGTX is up 77.6% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 45.1%.
TG Therapeutics trades at 19.3x its trailing twelve-month earnings per share of $2.75. Its forward P/E of 19.6x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year. TG Therapeutics's next earnings report is expected on Nov 2, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About TG Therapeutics
Company profileTG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Michael S. Weiss Esq., J.D.
- Headquarters
- Morrisville, NC
- Employees
- 399
- Website
- tgtherapeutics.com
Financial highlights
Full financialsIn fiscal 2025, TG Therapeutics generated $616.3 million in revenue, up 87.3% from fiscal 2024, its 3rd consecutive year of revenue growth. Net income was $447.2 million (+1812.4% year over year), for a net margin of 72.6% versus a median of -5204.1% in the prior 5 years. Gross margin was 83.7% (down from 88.3%) and operating margin 20.0%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $616.29M | $329.00M | $233.66M | $2.79M | $6.69M |
| Growth | +87.32% | +40.80% | +8290.02% | -58.36% | +4300.66% |
| Net income | $447.18M | $23.38M | $12.67M | $-223.81M | $-348.10M |
| EPS (diluted) | $2.77 | $0.15 | $0.09 | $-1.65 | $-2.63 |
Analyst forecast
ForecastConsensus (8 analysts)
strong_buy
Avg. price target
$69.71+31.65%
- Strong buy 1
- Buy 6
- Hold 0
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 2, 2026
- EPS estimate
- $0.36
- Last reported (Q2 2026)
- Aug 5, 2026
- EPS actual vs est.
- $0.05 vs —
TG Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PRAXPraxis Precision Medicines Inc. | 278.02 | -0.76% | $7.76B | vs TGTX |
| ABVXAbivax SA ADR | 87.01 | -1.37% | $7.59B | vs TGTX |
| CYTKCytokinetics Incorporated | 61.12 | -0.37% | $8.50B | vs TGTX |
| SYRESpyre Therapeutics Inc. | 80.85 | +0.92% | $7.46B | vs TGTX |
| IONSIonis Pharmaceuticals Inc. | 44.16 | +0.36% | $7.34B | vs TGTX |
| ARWRArrowhead Pharmaceuticals Inc. | 61.48 | -0.10% | $8.68B | vs TGTX |
| ALKSAlkermes plc | 41.45 | -0.49% | $6.95B | vs TGTX |
| AXSMAxsome Therapeutics Inc. | 172.97 | -0.79% | $9.06B | vs TGTX |
Indexes, lists and sector
TG Therapeutics stock FAQ
What is TG Therapeutics's stock price today?
TGTX last traded at $52.95 as of Oct 7, 4:00 PM EDT, up 1.46% on the day. Prices are delayed at least 15 minutes.
Does TG Therapeutics pay a dividend?
No. TG Therapeutics does not currently pay a regular cash dividend.
When is TG Therapeutics's next earnings date?
TG Therapeutics is expected to report earnings on Monday, November 2, 2026. Analysts expect EPS of $0.36.
What is TGTX's P/E ratio?
TGTX trades at a trailing P/E ratio of 19.25 and a forward P/E of 19.55.
Who is TG Therapeutics's CEO?
Mr. Michael S. Weiss Esq., J.D. is the chief executive officer of TG Therapeutics Inc., which has about 399 employees.
Has TGTX ever split its stock?
Yes. The most recent TGTX stock split was a 100-for-5625 split on Apr 30, 2012, one of 2 splits on record.
What is the TGTX 52-week high?
The 52-week high for TGTX is $59.30 and the 52-week low is $26.76. The stock is currently 10.7% below its high.